

# David OMalley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3749553/publications.pdf>

Version: 2024-02-01

48  
papers

3,503  
citations

236925

25  
h-index

214800

47  
g-index

48  
all docs

48  
docs citations

48  
times ranked

3490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 191-226.	4.9	356
2	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine, 2019, 380, 2317-2326.	27.0	326
3	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal of Clinical Oncology, 2018, 36, 2044-2051.	1.6	313
4	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. New England Journal of Medicine, 2016, 374, 738-748.	27.0	303
5	NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 896-909.	4.9	200
6	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. Journal of Clinical Oncology, 2022, 40, 752-761.	1.6	189
7	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of Clinical Oncology, 2017, 35, 1112-1118.	1.6	158
8	Ovarian Cancer, Version 3.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1339-1349.	4.9	151
9	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 2022, 40, 3952-3964.	1.6	125
10	Ovarian Cancer, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1199-1209.	4.9	119
11	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	12.8	116
12	Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2016, 34, 3854-3863.	1.6	112
13	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology, 2020, 157, 379-385.	1.4	89
14	Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2009, 113, 11-17.	2.4	83
15	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of Clinical Oncology, 2020, 38, 3753-3762.	1.6	82
16	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of Clinical Oncology, 2022, 40, 762-771.	1.6	71
17	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. Journal of Clinical Oncology, 2021, 39, 3623-3632.	1.6	69
18	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2018, 36, 3324-3330.	1.6	61

#	ARTICLE	IF	CITATIONS
19	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2021, 163, 274-280.	1.4	59
20	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 269-272.	1.4	49
21	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRI±)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 46-52.	1.4	48
22	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>JAMA Oncology</i> , 2016, 2, 1427.	7.1	45
23	Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence. <i>Gynecologic Oncology</i> , 2010, 116, 10-14.	1.4	40
24	The role of robotic surgery in endometrial cancer. <i>Journal of Surgical Oncology</i> , 2015, 112, 761-768.	1.7	30
25	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3494-3505.	1.6	28
26	Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2019, 152, 316-321.	1.4	27
27	Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1717-1721.	2.5	26
28	Is bariatric surgery an option for women with gynecologic cancer? Examining weight loss counseling practices and training among gynecologic oncology providers. <i>Gynecologic Oncology</i> , 2014, 134, 540-545.	1.4	25
29	Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. <i>Gynecologic Oncology</i> , 2014, 135, 90-94.	1.4	22
30	RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. <i>Future Oncology</i> , 2021, 17, 3433-3443.	2.4	21
31	Outpatient desensitization in selected patients with platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2017, 145, 603-610.	1.4	20
32	Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 625.e1-625.e14.	1.3	18
33	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 682-686.	2.5	16
34	Perceptions of weight management counseling among gynecologic cancer survivors: opportunities for enhancing survivorship care. <i>Supportive Care in Cancer</i> , 2017, 25, 1537-1545.	2.2	16
35	Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour) Tj ETQq1 1 0.784314 rgBT /Overloc <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1331-1336.	2.5	15
36	The Use of Transvaginal Ultrasound in Type II Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 858-862.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Antibody-drug conjugates for the treatment of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 875-887.	3.1	11
38	Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. <i>Advances in Therapy</i> , 2022, 39, 328-345.	2.9	9
39	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 833-838.	2.5	7
40	A Rare Case of Atypical Placental Site Nodule With an Emerging Intermediate Trophoblastic Tumor. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 238-246.	1.4	7
41	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	2.5	7
42	Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 35-42.	2.5	6
43	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	2.8	4
44	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 660-661.	0.4	3
45	Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 21-25.	1.7	3
46	Progress in Gynecologic Cancers with Antibody Drug Conjugates. <i>Current Oncology Reports</i> , 2021, 23, 89.	4.0	3
47	How safe is rucaparib in ovarian cancer?. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1249-1255.	2.4	1
48	Reply to G.B. Holt. <i>Journal of Clinical Oncology</i> , 2016, 34, 1016-1017.	1.6	0